Trials / Terminated
TerminatedNCT02598310
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Osaka Medical College · Academic / Other
- Sex
- Female
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nab-paclitaxel | nab-paclitaxel 260mg/m2 q3w |
| DRUG | Trastuzumab | trastuzumab 6 mg/kg (8 mg/kg as the loading dose) |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-11-30
- Completion
- 2018-11-30
- First posted
- 2015-11-05
- Last updated
- 2019-08-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02598310. Inclusion in this directory is not an endorsement.